Drug Research
Boehringer Ingelheim Integrates Owkin K Pro AI to Accelerate Drug Discovery
Boehringer Ingelheim has joined other pharmaceutical leaders in deploying Owkin's agentic AI scientist, K Pro, to analyze multimodal patient data in oncology and immunology R&D.
Drug Research
EMA Initiates Data Sharing Pilot for New Approach Methodologies
The European Medicines Agency has launched a voluntary framework for sharing data from non-animal testing methods to build regulatory confidence and refine drug development.
Business & Industry
Novartis Signs $3.22 Billion Deal with Alteogen for Subcutaneous Drug Technology
Novartis has signed a landmark agreement with South Korean biopharmaceutical firm Alteogen, potentially valued at up to $3.22 billion, for the development and commercialisation of subcutaneous drug formulations powered by Alteogen's proprietary ALT-B4 technology.
A Multi-Option Agreement Targeting Subcutaneous Formulation
The...
News
How Prescription Medications Can Impair Driving Ability
Medication safety is not limited to achieving the intended therapeutic effect. In 2024, the US Food and Drug Administration (FDA) published an article titled ‘Some Medicines and Driving Don’t Mix,’ and there is much truth to that.
Many prescription medications...
Business & Industry
Novo Nordisk and AWS Enter Strategic AI Partnership to Accelerate Drug Discovery
Novo Nordisk has announced a strategic partnership with Amazon Web Services (AWS), naming it its preferred cloud provider and strategic AI partner, with the shared goal of accelerating drug discovery and modernising the company's technology infrastructure to prepare for...
Business & Industry
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals
The Trump administration is preparing to announce a new round of voluntary drug-pricing agreements with midsize biotech companies as early as August 31, 2026, according to sources familiar with the matter.
The companies involved are expected to offer discounts on...
Business & Industry
Huawei Expands AI Drug Discovery Ambitions Amid Domestic Chip Push and Policy Support
Huawei intends to deepen its artificial intelligence partnerships with pharmaceutical companies, according to William Zhang, president of the company's healthcare business unit, who confirmed to Reuters that the firm's current AI drug projects run predominantly with domestic Chinese drugmakers....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read














